External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

ESMO IO 2025

December 10 - December 12

London, United Kingdom

ESMO Immuno-Oncology Congress 2025

Add to calendar

Medical Materials

Agenda

Coming soon

05:15 PM

Duration 75mins London, United Kingdom

IMreal Cohort 5: Interim analysis of patients with PD-L1–high metastatic non-small cell lung cancer treated with first-line atezolizumab in the real-world setting of routine clinical practice

JOSE LUIS PEREZ GRACIA, Nicolas Girard, Sanjay Popat, Stefaniya Shoshkova, Sunil Sharma

Oncology | Non Small Cell Lung Carcinoma

Add to calendar

Duration 75mins London, United Kingdom

Lurbinectedin + atezolizumab as first-line (1L) maintenance treatment in patients with extensive-stage small-cell lung cancer (ES-SCLC): Exploratory results of biomarker, updated efficacy and safety analyses from the Phase III IMforte trial

Bhatt Kamalnayan, Debasis Chakrabarti, George Cai, Hossein Borghaei, Juan Vazquez Limon, Katarzyna Stencel, Konstantinos Syrigos, LUIS PAZ-ARES RODRIGUEZ, Lisa Lin, Margarita Majem Tarruella, Martin Reck, Mehmet Artac, Roy Herbst, Solange Peters, Stephen Liu, Vaikunth Cuchelkar, Vilma Graupner

Oncology | Small Cell Lung Cancer

Add to calendar

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.